UCB (PK) Aktie - UCBJY

Professionelle Tools für Privatanleger.

Premium

Current Price

96,17

Gebot

96,04

Fragen

96,17

Volumen

8.533

94,23 Tagesbereich 96,41

50,77 52-Wochen-Bereich 100,66

Marktkapitalisierung

36,467B

Handelsende

94,31

Handelsbeginn

94,59

Letzte Trade

95.99

Letzter Handelszeitpunkt

19:29:52

Finanzvolumen

US$ 816.681

VWAP

95,7085

Durchschnittliches Volumen (3 Mio.)

19.351

Ausgegebene Aktien

379.189.796

Dividendenrendite

0.96%

Kurs-Gewinn-Verhältnis

203,57

Gewinn pro Aktie (EPS)

0,9

Erlöse

4,87B

Nettogewinn

343M

UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Sektor

Pharmaceutical Preparations

Branche

Chemicals & Allied Products

Website

www.ucb.com

Hauptsitz

Brussels, Brussels-capital Region, Bel

Gegründet

1928

UCB (PK) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker UCBJY. The last closing price for UCB (PK) was US$94,31. Over the last year, UCB (PK) shares have traded in a share price range of US$ 50,77 to US$ 100,66.

UCB (PK) currently has 379.189.796 shares in issue. The market capitalisation of UCB (PK) is US$35,76 billion. UCB (PK) has a price to earnings ratio (PE ratio) of 203.57.

UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services

UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services Judges highlight value-added partnership and finance...

New Data Identify Important Factors that May Reduce Hospitalizations among People with Epilepsy in the U.S.

New Data Identify Important Factors that May Reduce Hospitalizations among People with Epilepsy in the U.S. Results of retrospective analysis...

UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015

UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015 PR Newswire ATLANTA, May 16, 2015 ATLANTA, May 16, 2015...

UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam

UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam - Major milestone for brivaracetam is latest...

UCB and Emory Present New Assessment of Epilepsy Prevalence and Incidence in the U.S. at 2014 American Epilepsy Society Annua...

UCB and Emory Present New Assessment of Epilepsy Prevalence and Incidence in the U.S. at 2014 American Epilepsy Society Annual Meeting PR...

UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of...

UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-1.48	-1.51561699949	97.65	99.47	94.23	48129	97.27189776	DR
4	1.26	1.32757349068	94.91	100.062	94.23	40930	97.2953192	DR
12	0.19	0.197957907897	95.98	100.66	93.22	19351	97.36428322	DR
26	11.83	14.0265591653	84.34	100.66	84.31	18499	95.53614331	DR
52	44.58	86.4120953673	51.59	100.66	50.77	19331	82.39684154	DR
156	46.42	93.3065326633	49.75	100.66	32.82	21145	53.82668412	DR
260	46.82	94.8733535968	49.35	100.66	32.45	20438	54.10019083	DR

UCBJY - Frequently Asked Questions (FAQ)

What is the current UCB (PK) share price?

The current share price of UCB (PK) is US$ 96,17

How many UCB (PK) shares are in issue?

UCB (PK) has 379.189.796 shares in issue

What is the market cap of UCB (PK)?

The market capitalisation of UCB (PK) is USD 35,76B

What is the 1 year trading range for UCB (PK) share price?

UCB (PK) has traded in the range of US$ 50,77 to US$ 100,66 during the past year

What is the PE ratio of UCB (PK)?

The price to earnings ratio of UCB (PK) is 203,57

What is the cash to sales ratio of UCB (PK)?

The cash to sales ratio of UCB (PK) is 14,35

What is the reporting currency for UCB (PK)?

UCB (PK) reports financial results in EUR

What is the latest annual turnover for UCB (PK)?

The latest annual turnover of UCB (PK) is EUR 4,87B

What is the latest annual profit for UCB (PK)?

The latest annual profit of UCB (PK) is EUR 343M

What is the registered address of UCB (PK)?

The registered address for UCB (PK) is 60, ALLEE DE LA RECHERCHE, BRUSSELS, BRUSSELS-CAPITAL REGION, B-1070

What is the UCB (PK) website address?

The website address for UCB (PK) is www.ucb.com

Which industry sector does UCB (PK) operate in?

UCB (PK) operates in the CHEMICALS & ALLIED PRODUCTS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
ELYSElys BMG Group Inc (CE)	US$ 0,0004 (39.900,00%)	5,1k
YRIVYangtze River Port and Logistics Ltd (CE)	US$ 0,0001 (9.900,00%)	2,39k
SIRCSolar Integrated Roofing Corporation (PK)	US$ 0,0001 (9.900,00%)	12,77M
NXTPNextPlay Technologies Inc (CE)	US$ 0,0001 (9.900,00%)	2,15k
MFLTYMissfresh Ltd (CE)	US$ 0,0001 (9.900,00%)	103
FVTIFortune Valley Treasures Inc (CE)	US$ 0,0015 (-99,40%)	588
EGRNFChina Evergrande Group (CE)	US$ 0,0001 (-99,01%)	5k
FHBCFernhill Beverage Inc (CE)	US$ 0,000001 (-99,00%)	9,5k
AHFDActive Health Foods Inc (CE)	US$ 0,000001 (-99,00%)	500k
BRAVBravada International Limited (CE)	US$ 0,000001 (-99,00%)	188,96k
RDARRaadr Inc (PK)	US$ 0,0008 (14,29%)	120,61M
GTLLGlobal Technologies Ltd (PK)	US$ 0,0001 (-66,67%)	111,08M
RONNRonn Motor Group Inc (PK)	US$ 0,0003 (0,00%)	105,41M
BYOCBeyond Commerce Inc (PK)	US$ 0,0001 (-50,00%)	84,78M
HCMCHealthier Choices Management Corporation (PK)	US$ 0,000001 (0,00%)	65M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

UCB (PK) (UCBJY)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über UCB (PK)

UCBJY Neueste Nachrichten

UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services

New Data Identify Important Factors that May Reduce Hospitalizations among People with Epilepsy in the U.S.

UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015

UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam

UCB and Emory Present New Assessment of Epilepsy Prevalence and Incidence in the U.S. at 2014 American Epilepsy Society Annua...

UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of...

UCB, Georgia Institute of Technology Partner to Harness the Power of Predictive Analytics in Epilepsy Care

UCB reinforces its leadership in epilepsy at the 2014 Annual Meeting of the American Epilepsy Society (AES)

UCB shows strong scientific presence at leading rheumatology meeting

Advent International and Avista Capital Partners to Acquire Kremers Urban Pharmaceuticals from UCB

UCBJY - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

UCB (PK) (UCBJY) Börsenkurse

UCB (PK) (UCBJY)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über UCB (PK)

UCBJY Neueste Nachrichten

UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services

New Data Identify Important Factors that May Reduce Hospitalizations among People with Epilepsy in the U.S.

UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015

UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam

UCB and Emory Present New Assessment of Epilepsy Prevalence and Incidence in the U.S. at 2014 American Epilepsy Society Annua...

UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of...

UCB, Georgia Institute of Technology Partner to Harness the Power of Predictive Analytics in Epilepsy Care

UCB reinforces its leadership in epilepsy at the 2014 Annual Meeting of the American Epilepsy Society (AES)

UCB shows strong scientific presence at leading rheumatology meeting

Advent International and Avista Capital Partners to Acquire Kremers Urban Pharmaceuticals from UCB

UCBJY - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen